Research Analysts Set Expectations for Theratechnologies Inc’s FY2018 Earnings (TH)

Theratechnologies Inc (TSE:TH) – Equities research analysts at National Bank Financial upped their FY2018 earnings per share estimates for Theratechnologies in a research report issued to clients and investors on Thursday. National Bank Financial analyst E. Leno now expects that the company will post earnings of $0.35 per share for the year, up from their prior estimate of $0.28. National Bank Financial currently has a “Outperform” rating and a $9.75 price target on the stock.

Separately, Scotiabank reiterated an “outperform” rating and set a C$9.50 target price on shares of Theratechnologies in a research report on Wednesday, June 21st.

WARNING: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2017/10/09/research-analysts-set-expectations-for-theratechnologies-incs-fy2018-earnings-th.html.

Theratechnologies (TSE:TH) opened at 7.86 on Monday. The stock’s 50 day moving average price is $7.55 and its 200-day moving average price is $7.18. Theratechnologies has a 12 month low of $2.61 and a 12 month high of $8.72. The stock’s market cap is $584.90 million.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients

Theratechnologies Inc (TSE:TH) – Equities research analysts at National Bank Financial upped their FY2018 earnings per share estimates for Theratechnologies in a research report issued to clients and investors on Thursday. National Bank Financial analyst E. Leno now expects that the company will post earnings of $0.35 per share for the year, up from their prior estimate of $0.28. National Bank Financial currently has a “Outperform” rating and a $9.75 price target on the stock.

Separately, Scotiabank reiterated an “outperform” rating and set a C$9.50 target price on shares of Theratechnologies in a research report on Wednesday, June 21st.

WARNING: This story was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://ledgergazette.com/2017/10/09/research-analysts-set-expectations-for-theratechnologies-incs-fy2018-earnings-th.html.

Theratechnologies (TSE:TH) opened at 7.86 on Monday. The stock’s 50 day moving average price is $7.55 and its 200-day moving average price is $7.18. Theratechnologies has a 12 month low of $2.61 and a 12 month high of $8.72. The stock’s market cap is $584.90 million.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Earnings History and Estimates for Theratechnologies (TSE:TH)

Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply